UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of March 2021
001-40101
(Commission File Number)
BRIACELL THERAPEUTICS CORP.
(Exact name of Registrant as specified in its charter)
Suite 300 – 235 15th Street
West Vancouver, BC V7T 2X1
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BRIACELL THERAPEUTICS CORP.
EXHIBITS
Exhibit Number | Description | |
99.1 | Press Release, dated February 23, 2021, issued by BriaCell Therapeutics Corp. | |
99.2 | Press Release, dated February 26, 2021, issued by Briacell Therapeutics Corp. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BRIACELL THERASPEUTICS CORP. | ||
Date: March 1, 2021 | By: | /s/ William V. Williams |
William V. Williams | ||
Chief Executive Officer |